| Literature DB >> 34151148 |
Ramesh Nachimuthu1, Velu Rajesh Kannan2, Bulent Bozdogan3, Vaithilingam Krishnakumar2, Karutha Pandian S4, Prasanth Manohar5,6.
Abstract
Clinical pathogens, especially Gram-negative bacteria developing resistance to third-generation cephalosporins, are making clinical outcomes more complicated and serious. This study was undertaken to evaluate the distribution of CTX-M-type extended-spectrum β-lactamases (ESBLs) in Tamil Nadu, India. For this study, clinical samples were collected from five different hospitals located in Tamil Nadu and the ESBL-producing Gram-negative isolates were characterized. MIC was performed using cefotaxime and ceftazidime. The bla ESBL-producing genes were screened using multiplex PCR for the genes, CTX-M group-1, -2, -8, -9, -26. The conjugation studies were performed using Escherichia coli AB1157 as a recipient for the isolates harbouring plasmid-borne resistance following broth-mating experiment. In total, 1500 samples were collected and 599 Gram-negative bacteria were isolated that included E. coli (n=233), Klebsiella pneumoniae (n=182), Pseudomonas aeruginosa (n=79), Citrobacter spp. (n=30), Proteus mirabilis (n=28), Salmonella spp. (n=21), Acinetobacter baumannii (n=12), Serratia spp. (n=6), Shigella spp. (n=4), Morganella morganii (n=3) and Providencia spp. (n=1). MIC results showed that 358 isolates were resistant to cefotaxime and ceftazidime. Further, ESBL gene-amplification results showed that 19 isolates had CTX-M group-1 gene including E. coli (n=16), K. pneumoniae (n=2) and P. aeruginosa (n=1) whereas one M. morganii isolate had CTX-M group-9, which was plasmid-borne. Through conjugation studies, 12/20 isolates were found to be involved in the transformation of its plasmid-borne resistance gene. Our study highlighted the importance of horizontal gene transfer in the dissemination of plasmid-borne bla CTX-M-type resistance genes among the clinical isolates.Entities:
Keywords: CTX-M; ESBL; cefotaxime; cephalosporins; plasmid-borne resistance; transconjugation
Year: 2020 PMID: 34151148 PMCID: PMC8209704 DOI: 10.1099/acmi.0.000142
Source DB: PubMed Journal: Access Microbiol ISSN: 2516-8290
Fig. 1.Sampling locations: five different regions were selected in Tamil Nadu for sample collection.
The prevalence rate of Gram-negative bacteria isolated from the clinical samples between different age groups and sex
|
Clinical sample |
Age group |
Distribution of clinical samples and isolates |
Total no. of samples |
Total no. of isolates | |||||
|---|---|---|---|---|---|---|---|---|---|
|
Samples |
Isolates | ||||||||
|
Male |
Female |
|
Male |
Female |
| ||||
|
Urine |
Below 15 |
80 |
90 |
0.087 |
38 |
49 |
0.0001 |
815 |
346 |
|
b/w15-45 |
172 |
163 |
91 |
96 | |||||
|
Above 45 |
138 |
172 |
32 |
40 | |||||
|
Blood |
Below 15 |
17 |
11 |
0.193 |
2 |
7 |
0.076 |
126 |
44 |
|
b/w15-45 |
41 |
22 |
6 |
18 | |||||
|
Above 45 |
12 |
23 |
3 |
8 | |||||
|
Pus |
Below 15 |
8 |
13 |
0.441 |
6 |
9 |
0.190 |
152 |
55 |
|
b/w15-45 |
44 |
36 |
8 |
15 | |||||
|
Above 45 |
19 |
32 |
2 |
15 | |||||
|
Stool |
Below 15 |
21 |
21 |
0.399 |
5 |
18 |
0.025 |
195 |
80 |
|
b/w15-45 |
53 |
42 |
10 |
31 | |||||
|
Above 45 |
29 |
29 |
6 |
10 | |||||
|
Endotracheal secretion |
Below 15 |
3 |
2 |
0.843 |
1 |
2 |
0.333 |
25 |
10 |
|
b/w15-45 |
6 |
7 |
1 |
6 | |||||
|
Above 45 |
4 |
3 |
0 |
0 | |||||
|
Sputum |
Below 15 |
9 |
6 |
0.885 |
2 |
3 |
0.433 |
49 |
16 |
|
b/w15-45 |
11 |
13 |
1 |
5 | |||||
|
Above 45 |
5 |
5 |
1 |
4 | |||||
|
Semen |
Below 15 |
1 |
2 |
0.185 |
0 |
2 |
0.529 |
20 |
2 |
|
b/w15-45 |
7 |
4 |
0 |
0 | |||||
|
Above 45 |
5 |
1 |
0 |
0 | |||||
|
Vaginal swab |
Below 15 |
0 |
1 |
0.725 |
0 |
0 |
1.000 |
8 |
2 |
|
b/w15-45 |
1 |
3 |
1 |
0 | |||||
|
Above 45 |
2 |
1 |
0 |
1 | |||||
|
Cerebrospinal fluid |
Below 15 |
1 |
0 |
0.499 |
0 |
0 |
0.529 |
1 |
2 |
|
b/w15-45 |
0 |
0 |
0 |
1 | |||||
|
Above 45 |
0 |
0 |
0 |
1 | |||||
|
Throat swab |
Below 15 |
2 |
2 |
0.813 |
0 |
1 |
1.000 |
17 |
4 |
|
b/w15-45 |
3 |
4 |
0 |
1 | |||||
|
Above 45 |
4 |
2 |
1 |
1 | |||||
|
Wound swab |
Below 15 |
11 |
9 |
0.409 |
2 |
7 |
0.185 |
75 |
31 |
|
b/w15-45 |
16 |
17 |
2 |
12 | |||||
|
Above 45 |
14 |
8 |
4 |
4 | |||||
|
Tracheoscopy |
Below 15 |
1 |
0 |
0.373 |
0 |
1 |
0.529 |
4 |
2 |
|
b/w15-45 |
2 |
1 |
0 |
1 | |||||
|
Above 45 |
0 |
0 |
0 |
0 | |||||
|
Bronchial wash |
Below 15 |
3 |
2 |
0.506 |
1 |
2 |
1.000 |
8 |
3 |
|
b/w15-45 |
1 |
1 |
0 |
0 | |||||
|
Above 45 |
1 |
0 |
0 |
0 | |||||
|
Catheter tip |
Below 15 |
0 |
1 |
1.000 |
0 |
1 |
0.529 |
5 |
2 |
|
b/w15-45 |
2 |
0 |
0 |
0 | |||||
|
Above 45 |
0 |
2 |
0 |
0 | |||||
P-value = male vs female. b/w, between. P<0.05 was considered as statistically significant.
Fig. 2.Distribution of Gram-negative bacteria among male and female patients in the five sampling locations.
Comparison of two different phenotypic test results used to identify the ESBL producer
|
Sampling location |
Distribution of ESBL producer-phenotypic analysis | |||
|---|---|---|---|---|
|
By disc-diffusion test |
By combination-disc method* | |||
|
Total isolates |
ESBL producer |
Total isolates |
ESBL producer | |
|
|
333 |
281 (84.3) |
281 |
188 (66.9) |
|
|
47 |
34 (72.3) |
34 |
34 (100) |
|
|
120 |
98 (81.6) |
98 |
79 (88.7) |
|
|
39 |
31 (79.4) |
31 |
28 (90.3) |
|
|
40 |
38 (95) |
38 |
22 (57.8) |
|
|
20 |
16 (80) |
16 |
07 (43.7) |
|
|
599 |
498 (83.1) |
498 |
358 (71.8) |
*Bacterial isolates that were found to be a ESBL producer using the disc-diffusion method was further studied for the combination-disc method.
Minimal Inhibitory Concentration (MIC) results of the isolates as determined using cefotaxime and ceftazidime
|
Sampling location |
MIC results as obtained by micro-broth dilution method* | |||
|---|---|---|---|---|
|
Cefotaxime (≤ 256 µg ml−1) |
Cefotaxime (≥ 256 µg ml−1) |
Ceftazidime (≤ 256 µg ml−1) |
Ceftazidime (≥ 256 µg ml−1) | |
|
|
170 |
18 |
175 |
9 |
|
|
28 |
4 |
25 |
7 |
|
|
70 |
8 |
68 |
13 |
|
|
28 |
2 |
27 |
1 |
|
|
21 |
2 |
19 |
6 |
|
|
5 |
2 |
4 |
4 |
|
|
322 (89.9) |
36 (10.4) |
318 (88.8) |
40 (11.4) |
|
358 |
358 | |||
*Bacterial isolates that were found to be ESBL producers by earlier phenotypic studies were taken for MIC determination.